spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  insulin resistance 

 HSMN NewsFeed - 30 Nov 2017
Fractyl Appoints Senator William W. Bradley and Dr. John Amatruda to the Company's Board of Directors
Devices Endocrinology Personnel
 HSMN NewsFeed - 30 Nov 2017
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
Devices Endocrinology Venture Capital
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 8 Nov 2016
BD Launches First Syringe Designed for Use with Humulin(R) R U-500 Insulin
Devices Drug Delivery Endocrinology Product Launch
 HSMN NewsFeed - 27 Jan 2016
MetaCure Announces Appointment of New CEO
Devices Endocrinology Personnel
 HSMN NewsFeed - 19 Nov 2015
Fractyl Announces Completion of $57 Million Series C Investment
Devices Endocrinology Venture Capital
 HSMN NewsFeed - 5 Aug 2015
Metacrine Raises $36 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 12 Jul 2013
American Association Of Clinical Endocrinologists (AACE) Endorses Measurement Of Low-Density Lipoprotein Particle (LDL-P) Number
Diagnostics Endocrinology
 HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 17 Aug 2012
Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
Biopharmaceuticals Generics Endocrinology
 HSMN NewsFeed - 13 Feb 2012
Medtronic Launches Two New Clinical Programs to Evaluate the Use of Symplicity(TM) 1 Renal Denervation System across Multiple Conditions
Devices Cardiology
 HSMN NewsFeed - 19 Jan 2012
Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 8 Dec 2010
Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2010
Ardian(R) Demonstrates 2-Year Durability of Blood Pressure Reduction in Hypertension Patients Treated with Symplicity(R) Catheter System(TM)
Devices Cardiology
 HSMN NewsFeed - 3 Jun 2010
Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension
Devices Interventional Cardiology
 HSMN NewsFeed - 10 May 2010
InteKrin Therapeutics Appoints Linda Higgins, PhD as President and Chief Executive Officer. Company Founder Denny Lanfear Named Chairman of the Board.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2010
InteKrin Therapeutics Appoints Roman Skowronski, MD, PhD as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 2 Nov 2009
Pico-Tesla Starts Pilot Study for Type 2 Diabetes with its Proprietary Magnetic (Magneceutical) Therapy
Devices Endocrinology
 HSMN NewsFeed - 21 Oct 2009
Wellstat Therapeutics and sanofi-aventis Enter Agreement on Novel Therapy for Type II Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 28 Sep 2009
MSD Receives Positive CHMP Opinion for 'Januvia(R)' and 'Janumet(R)' as Add-On to Insulin in the European Union
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 14 Sep 2009
InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2009
FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 5 May 2009
Merck Serono Launches Glucophage Powder in First European Countries
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 9 Mar 2009
DiaMedica Appoints Stephen J. Waters as Interim Chief Scientific Officer
Biopharmaceuticals Endocrinology Personnel
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 24 Jun 2008
FDA Approves PrandiMet(TM), a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 16 Jun 2008
Tercica Announces Results from Increlex(R) IGFD Patient Registry and Other Increlex(R) Studies at the 90th Meeting of the Endocrine Society
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Apr 2008
AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 31 Mar 2008
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 10 Jan 2008
Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory
Diagnostics Endocrinology Venture Capital
 HSMN NewsFeed - 8 Nov 2007
InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2007
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 22 Oct 2007
Acumen Co-Founders Link Alzheimer's Cause to Insulin Resistance
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Oct 2007
Amarin Announces Initiation of Cardiovascular Development Strategy
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2007
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
Takeda Statement on ACTOS(R) (pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 22 Aug 2007
Bariatric Surgical Society Takes on New Name, New Mission and New Surgery
Surgery Endocrinology
 HSMN NewsFeed - 9 Aug 2007
IPSEN: Increlex(R) Receives Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Aug 2007
Tercica Receives Marketing Approval for Increlex in the European Union
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 23 Jun 2007
Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus(R) Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 22 Jun 2007
Encapsulation Systems Previews the U-Strip(TM) Insulin Patch, the Next Generation of Transdermal Drug Delivery for the Treatment of Diabetes
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 6 Jun 2007
Takeda Revises ACTOS(R) (pioglitazone HCl) Prescribing Label
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 25 May 2007
Ipsen: Increlex(R) Receives CHMP Positive Opinion for the Treatment of Severe Primary IGF-1 Deficiency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Apr 2007
Metabolex Raises $32 Million to Accelerate Clinical Development Programs for Its Pipeline of Drug Candidates in Metabolic Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Apr 2007
GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 16 Apr 2007
Diobex Raises $24 Million Series B Financing Led by Inventages Venture Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 2 Apr 2007
FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 6 Mar 2007
Litigation Settlement Reached Between Tercica, Genentech and Insmed
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Jan 2007
Zylera Pharmaceuticals Announces Availability of RELAMINE for the Treatment of Osteoarthritis
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2007
Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Jan 2007
InteKrin Therapeutics Licenses Diabetes Product
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 10 Jan 2007
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
Biopharmaceuticals Neurology Licensing Distribution
 HSMN NewsFeed - 3 Jan 2007
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 5 Dec 2006
New Data Shows Rimonabant Benefited Patients with Type 2 Diabetes by Improving Blood Sugar Control, Reducing Weight and Acting on Other Cardiometabolic Risk Factors
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 4 Dec 2006
Landmark Study Shows Avandia(R) (rosiglitazone maleate) Is More Effective Than Metformin or a Sulfonylurea in Long-Term Blood Sugar Control in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 13 Nov 2006
New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2006
Former Amgen Manufacturing Executive Joins Insmed
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Oct 2006
FDA Approves Once-Daily JANUVIA(TM), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 16 Oct 2006
Insmed Sues Tercica for False Advertising
Biopharmaceuticals Litigation
 HSMN NewsFeed - 5 Oct 2006
Insmed Provides Update Concerning Virginia Unfair Competition Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 21 Sep 2006
Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 15 Sep 2006
Avandia(R) (rosiglitazone maleate) Reduced Risk of Progression From Pre-Diabetes To Type 2 Diabetes by 62 Percent in Largest Completed Diabetes Prevention Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Sep 2006
ACTOS(R) (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 21 Jul 2006
Takeda Announces Start of Phase 3 Clinical Program in the U.S. of Fixed Dose Combination Product of Actos(R) + TAK-536 for Treatment of Patients with Type 2 Diabetes Associated with Hypertension
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Jul 2006
GlaxoSmithKline Announces FDA Approval and the Launch of Avandamet(R) (Rosiglitazone Maleate and Metformin HCl) as Initial Therapy in the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 26 Jun 2006
Wythe Therapeutics and VeroScience Announce Worldwide License for Cycloset(R)
Biopharmaceuticals Endocrinology
Return to NewsFeed  

 Additional items found! 79

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 79 additional stories matching:
insulin resistance
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!